AMGN · 8-K · 20261103PR000153
Liquidity and Cash Position
AMGEN INC · 2026-11-03 · Importance 64 · Surprise 56 · From source text
Cash and cash equivalents totaled $13.190 billion at September 30, 2026, compared with $9.445 billion at September 30, 2025. Cash increased by $4.061 billion over the first nine months of 2026, compared with a $2.528 billion decrease in the corresponding 2025 period. In the third quarter of 2026, cash decreased by $799 million, whereas it increased by $1.417 billion in the third quarter of 2025.
Key facts
- Cash and cash equivalents were $13,190 million at September 30, 2026, compared with $9,445 million at September 30, 2025. source
- Amgen had $13.2 billion of cash and cash equivalents and $54.0 billion of debt outstanding as of September 30, 2026. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| cash | positive | realized | +3.9% | Cash and cash equivalents were $13,190 million at September 30, 2026, compared with $9,445 million at September 30, 2025. |